312 related articles for article (PubMed ID: 17236209)
21. Lipopeptides as dimerization inhibitors of HIV-1 protease.
Schramm HJ; de Rosny E; Reboud-Ravaux M; Büttner J; Dick A; Schramm W
Biol Chem; 1999 May; 380(5):593-6. PubMed ID: 10384967
[TBL] [Abstract][Full Text] [Related]
22. Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: rethinking the "fireman's grip" hypothesis.
Strisovsky K; Tessmer U; Langner J; Konvalinka J; Kräusslich HG
Protein Sci; 2000 Sep; 9(9):1631-41. PubMed ID: 11045610
[TBL] [Abstract][Full Text] [Related]
23. The structural stability of the HIV-1 protease.
Todd MJ; Semo N; Freire E
J Mol Biol; 1998 Oct; 283(2):475-88. PubMed ID: 9769219
[TBL] [Abstract][Full Text] [Related]
24. Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?
Towler EM; Gulnik SV; Bhat TN; Xie D; Gustschina E; Sumpter TR; Robertson N; Jones C; Sauter M; Mueller-Lantzsch N; Debouck C; Erickson JW
Biochemistry; 1998 Dec; 37(49):17137-44. PubMed ID: 9860826
[TBL] [Abstract][Full Text] [Related]
25. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
[TBL] [Abstract][Full Text] [Related]
26. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
27. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.
Shultz MD; Ham YW; Lee SG; Davis DA; Brown C; Chmielewski J
J Am Chem Soc; 2004 Aug; 126(32):9886-7. PubMed ID: 15303839
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site.
Skalova T; Dohnalek J; Duskova J; Petrokova H; Hradílek M; Soucek M; Konvalinka J; Hasek J
J Med Chem; 2006 Sep; 49(19):5777-84. PubMed ID: 16970402
[TBL] [Abstract][Full Text] [Related]
29. Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3.
Heaslet H; Kutilek V; Morris GM; Lin YC; Elder JH; Torbett BE; Stout CD
J Mol Biol; 2006 Mar; 356(4):967-81. PubMed ID: 16403521
[TBL] [Abstract][Full Text] [Related]
30. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
[TBL] [Abstract][Full Text] [Related]
31. Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies.
Bartonová V; Král V; Sieglová I; Brynda J; Fábry M; Horejsí M; Kozísek M; Sasková KG; Konvalinka J; Sedlácek J; Rezácová P
Antiviral Res; 2008 Jun; 78(3):275-7. PubMed ID: 18329737
[TBL] [Abstract][Full Text] [Related]
32. Carbonylhydrazide-based molecular tongs inhibit wild-type and mutated HIV-1 protease dimerization.
Dufau L; Marques Ressurreição AS; Fanelli R; Kihal N; Vidu A; Milcent T; Soulier JL; Rodrigo J; Desvergne A; Leblanc K; Bernadat G; Crousse B; Reboud-Ravaux M; Ongeri S
J Med Chem; 2012 Aug; 55(15):6762-75. PubMed ID: 22800535
[TBL] [Abstract][Full Text] [Related]
33. Sidechain-linked inhibitors of HIV-1 protease dimerization.
Bowman MJ; Chmielewski J
Bioorg Med Chem; 2009 Feb; 17(3):967-76. PubMed ID: 18337105
[TBL] [Abstract][Full Text] [Related]
34. Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M.
Ode H; Neya S; Hata M; Sugiura W; Hoshino T
J Am Chem Soc; 2006 Jun; 128(24):7887-95. PubMed ID: 16771502
[TBL] [Abstract][Full Text] [Related]
35. Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease.
Wondrak EM; Louis JM
Biochemistry; 1996 Oct; 35(39):12957-62. PubMed ID: 8841142
[TBL] [Abstract][Full Text] [Related]
36. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
Tsantrizos YS
Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
[TBL] [Abstract][Full Text] [Related]
37. Unfolding kinetics of tryptophan side chains in the dimerization and hinge regions of HIV-I protease tethered dimer by real time NMR spectroscopy.
Panchal SC; Hosur RV
Biochem Biophys Res Commun; 2000 Mar; 269(2):387-92. PubMed ID: 10708562
[TBL] [Abstract][Full Text] [Related]
38. Switching between allosteric and dimerization inhibition of HIV-1 protease.
Bowman MJ; Byrne S; Chmielewski J
Chem Biol; 2005 Apr; 12(4):439-44. PubMed ID: 15850980
[TBL] [Abstract][Full Text] [Related]
39. Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes.
Rezácová P; Pokorná J; Brynda J; Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezác J; Grantz Sasková K; Sieglová I; Plesek J; Sícha V; Grüner B; Oberwinkler H; Sedlácek' J; Kräusslich HG; Hobza P; Král V; Konvalinka J
J Med Chem; 2009 Nov; 52(22):7132-41. PubMed ID: 19874035
[TBL] [Abstract][Full Text] [Related]
40. Effects of remote mutation on the autolysis of HIV-1 PR: X-ray and NMR investigations.
Kumar M; Kannan KK; Hosur MV; Bhavesh NS; Chatterjee A; Mittal R; Hosur RV
Biochem Biophys Res Commun; 2002 Jun; 294(2):395-401. PubMed ID: 12051725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
